Paolo Tarantino: DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my friend and mentor of many years Giuseppe Curigliano

Paolo Tarantino shared on X:

“DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my friend and mentor of many years Giuseppe Curigliano.

The trial, announced to be positive, may have a major impact on treatment sequencing and on the definition of HER2. Set your alarm clocks early on Sunday, make sure not to miss it.”

Source: Paolo Tarantino/X

Paolo Tarantino holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.